AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Now, six months into the NSW Pharmacy Dermatology Trial, pharmacists are now also appropriately trained to manage impetigo ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Health Minister Ryan Park has rejected warnings from GPs, instead pushing ahead with plans to expand a range of medical ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

Discover a recent study that has investigated the efficacy of excimer light and topical methotrexate 1% hydrogel in managing ...